The report delivers a comprehensive analysis of global biologics sales. Covering cancer antibodies, non-TNF inflammatory mAbs, biosimilars, gene therapy, RNA-based drugs, and more, the report provides ...

Although advanced biologics offer hope, their high prices add to the distress. Fortunately, now more affordable biosimilars- nearly identical to biologics – can substantially reduce costs. Therapeutic ...

The denosumab biosimilar market is poised for disruption with 3 FDA-approved biosimilars, at least 5 awaiting approval, and launches anticipated to start in May 2025, while ongoing patent litigation ...

A panelist discusses how managing biosimilars requires close collaboration between payers and health systems to optimize patient care and cost savings, while sharing insights about program ...

Since the FDA’s groundbreaking approval of Zarxio in 2015, the US biosimilars market has surged to 67 approvals across 18 originators—though the journey has been anything but smooth, with adoption ...

The Global Oncology Biosimilars Market is expected to grow at 18.5% CAGR from 2025 to 2032. The latest Research report published by CMI with the title "An Increase in Demand and Opportunities for ...

and has been pivotal in advancing the company’s programs through establishing productive relationships and facilitating discussions with regulatory agencies regarding biosimilar development and ...

India's Biocon has expanded its pipeline of biosimilars with a $3.3 billion deal to acquire a portfolio of drugs from Viatris, the parent of its longstanding partner Mylan, which will boost its ...

Merilog is a rapid-acting human insulin analog and the first rapid-acting insulin biosimilar product approved by the Food and Drug Administration. HealthDay News — The U.S. Food and Drug ...

A London hospital is to investigate why over half of its patients with multiple sclerosis (MS) who switched from disease modifying therapy Tysabri (natalizumab) to biosimilar Tyruko have had to be ...

Jeff Auletta, MD, discusses his key takeaways from the 2025 Transplant and Cellular Therapy Meetings. Jeff Auletta, MD, senior vice president of health equity at the National Marrow Donor Program and ...

Bengaluru: BioconBiologics Ltd, a fully integrated global biosimilars company and a subsidiary of Biocon Ltd., has announced that YESINTEK (ustekinumab-kfce) is now available to patients in the United ...